STTK advances DR3 blockade for IBD; induction data slated for H1 2028
STTK is advancing DR3 blockade as a differentiated IBD approach, targeting superior maintenance efficacy and lower immunogenicity versus TL1A and IL-23 therapies. Induction data are expected in H1 2028 as trials continue.